SEXUALLY TRANSMITTED INFECTIONS (STI) PANEL
CUUR DiagnosticsTM is dedicated to maintaining the largest data set of infectious disease targets available in the world.
Sexually transmitted infections (STIs) are a public health problem, and their prevalence is only rising. It’s critical for diagnostic tests for STIs to not only aid the diagnosis of typical cases, but also atypical cases, asymptomatic infections and also multiple infections. Unfortunately, the existing diagnostic methods for STIs are fraught with several challenges, including delay in results, lack of sensitivity and specificity. CUUR Diagnostics methods fulfill the criteria of accuracy, affordability, accessibility, efficiency, sensitivity, specificity and ease of handling. Results are rapid, cost-effective and reliable; offering increased sensitivity, specificity and speed. CUUR Diagnostics methods are especially useful for microorganisms that cannot be or are difficult to cultivate by increasing automation and standardization and decreasing potential for human error.
|UTI Gram Positive Bacteria|
|UTI Gram Negative Bacteria|
D I A G N O S T I C S
- 2.3 million cases of chlamydia, gonorrhea and syphilis reported to CDC for 2017 and represents just a small fraction of the true disease burden
- The total estimated direct cost of STIs annually in the U.S. about $16 billion